Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
PMC6073405 BPC-157 angiogenic signaling VEGFR2-Akt-eNOS activation, nitric oxide bioavailability, FAK-paxillin cell-anchoring cascade, anti-cytokine modulation: PMC8275860 TB-4 / TB-500 G-actin sequestration and threshold-saturation mechanism actin-monomer binding, cytoskeletal mobilization for cell migration, mass-action pharmacodynamics requiring bolus dosing: PubMed 12581423 TB-4 Ac-SDKP anti-fibrotic fragment N-terminal tetrapeptide (fragment 14) released by meprin- and POP processing
Peptide Vials (GHK-Cu, 100 mg each): 5 days/week (1.0-2.0 mg/day): 8 weeks (~50 mg total): 1 vial 12 weeks (~90 mg total): 1 vial 16 weeks (~130 mg total): 2 vials 3 times/week (2 mg each): 8 weeks (~48 mg total): 1 vial 12 weeks (~72 mg total): 1 vial 16 weeks (~96 mg total): 1 vial Insulin Syringes (U-100, 29-31 gauge): 5 days/week: Per week: 5 syringes 8 weeks: 40 syringes 12 weeks: 60 syringes 16 weeks: 80 syringes 3 times/week: Per week: 3 syringes 8 weeks: 24 syringes 12 weeks: 36 syringes 16 weeks: 48 syringes Sterile or Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for the displayed calculation
Reported / Possible Side Effects Mild, anecdotal: Occasional reports of mild headache, transient jitteriness, or injection-site reactions
Bacteriostatic water resists this contamination, allowing the vial to be used across multiple reconstitutions over its shelf life
although inactivation of metH exclusively causes attenuation in non-anemic controls
